J Clin Endocrinol Metab:孕激素和睾酮联合注射可有效用于男性避孕

2016-10-28 MedSci MedSci原创

目前,仍未有一种安全有效的可逆性男性避孕方法。本研究旨在评估联用孕激素和睾酮注射抑制精子发生和避孕保护的效果。 采用前瞻性多中心研究设计,在十个研究中心,纳入18-45岁的健康男性,以及其18-38岁的女性伴侣,均无生育问题。 对男性参与者进行肌内注射庚酸炔诺酮200毫克和1000毫克睾酮,每8周给药一次。然后通过精液分析精子发生的抑制作用,通过妊娠率来评估避孕保护效果。 结果,

目前,仍未有一种安全有效的可逆性男性避孕方法。本研究旨在评估联用孕激素和睾酮注射抑制精子发生和避孕保护的效果。

采用前瞻性多中心研究设计,在十个研究中心,纳入18-45岁的健康男性,以及其18-38岁的女性伴侣,均无生育问题。

对男性参与者进行肌内注射庚酸炔诺酮200毫克和1000毫克睾酮,每8周给药一次。然后通过精液分析精子发生的抑制作用,通过妊娠率来评估避孕保护效果。

结果,在320名参与者中,95.9%的参与者(95%可信区间[CI],92.8-97.9)24周内精子浓度≤100万个/毫升。在长达56周的有效期内,266名男性参与者的伴侣仅有4名怀孕,怀孕率为 1.57%(95% CI,0.59-4.14)。52周后的抑制精子发生的累积可逆性恢复为94.8%(95% CI,91.5-97.1)。最常见的不良反应是痤疮、注射部位疼痛、性欲减退和情绪障碍。

该研究显示,联合孕激素和睾酮注射可近100%的抑制精子的发生,且效果可逆。与其他可供使用的男性可逆避孕方法相比,本研究所使用的方法避孕效果相对较好。但是该方法轻度至中度情绪障碍的频率相对较高。

原始出处:

Hermann M. Behre,et al., Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men. Journal of Clinical Endocrinology & Metabolism, October 27, 2016 DOI: 10.1210/jc.2016-2141.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


还在被临床的各种问题折磨?
还在为科研工作抓狂?
今天,我们用访谈的形式采访了各大医院的名咖,他们为我们解答临床各种疑难杂症;给我们提供成功的科研之路

点击此处,马上聆听!!!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1887579, encodeId=e3f8188e57948, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 21 06:17:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895968, encodeId=39ee18959683f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jan 07 05:17:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155338, encodeId=1767155338c8, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Nov 12 23:53:54 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155337, encodeId=2c4d15533ec9, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Nov 12 23:53:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385351, encodeId=fe40138535101, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Oct 30 06:17:00 CST 2016, time=2016-10-30, status=1, ipAttribution=)]
    2017-08-21 guojianrong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1887579, encodeId=e3f8188e57948, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 21 06:17:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895968, encodeId=39ee18959683f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jan 07 05:17:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155338, encodeId=1767155338c8, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Nov 12 23:53:54 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155337, encodeId=2c4d15533ec9, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Nov 12 23:53:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385351, encodeId=fe40138535101, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Oct 30 06:17:00 CST 2016, time=2016-10-30, status=1, ipAttribution=)]
    2017-01-07 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1887579, encodeId=e3f8188e57948, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 21 06:17:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895968, encodeId=39ee18959683f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jan 07 05:17:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155338, encodeId=1767155338c8, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Nov 12 23:53:54 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155337, encodeId=2c4d15533ec9, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Nov 12 23:53:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385351, encodeId=fe40138535101, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Oct 30 06:17:00 CST 2016, time=2016-10-30, status=1, ipAttribution=)]
    2016-11-12 xyfg98

    谢谢分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1887579, encodeId=e3f8188e57948, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 21 06:17:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895968, encodeId=39ee18959683f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jan 07 05:17:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155338, encodeId=1767155338c8, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Nov 12 23:53:54 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155337, encodeId=2c4d15533ec9, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Nov 12 23:53:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385351, encodeId=fe40138535101, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Oct 30 06:17:00 CST 2016, time=2016-10-30, status=1, ipAttribution=)]
    2016-11-12 xyfg98

    谢谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1887579, encodeId=e3f8188e57948, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 21 06:17:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895968, encodeId=39ee18959683f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jan 07 05:17:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155338, encodeId=1767155338c8, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Nov 12 23:53:54 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155337, encodeId=2c4d15533ec9, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Nov 12 23:53:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385351, encodeId=fe40138535101, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Oct 30 06:17:00 CST 2016, time=2016-10-30, status=1, ipAttribution=)]

相关资讯

JAMA Psychiatry:激素避孕与抑郁有什么关系?

近期的数据显示:使用激素避孕与首次使用抗抑郁药、诊断抑郁症的增加有关,尤其是15-19岁的青少年。 来自哥本哈根大学的Charlotte Wessel Skovlund硕士和同事们对1061997名年龄在15-34岁的女性进行了研究,调查使用激素避孕与随后抗抑郁药的使用和抑郁症的诊断之间的联系。从2000年到2013年,研究者对参与者平均随访了6.4年。队列的平均年龄为24.4岁。 与

更年期激素治疗是利是弊?

更年期是否需要激素治疗仍然是争议话题,为此国际绝经协会出台了最新的指南,为临床医生提供指导。

Am J Obstet Gynecol:左炔诺孕酮宫内缓释系统治疗子宫内膜不典型增生较口服孕激素更优

    我们试图探讨左炔诺孕酮宫内缓释系统(LNG-IUS)与口服孕激素(EH)治疗非典型性子宫内膜增生的疗效。进行PubMed,Scopus和中央数据库检索,到2014年8月为止,以及对相关的参考文献进行筛选。搜索仅限于人和女性的文献。本研究包括七个随机对照试验(n=766名女性)。主要观察指标为3、6、12、24个月后的治疗效果(组织学反应),不规则阴道出血率及子

Breast Cancer Res Treat:新的猜想:雌孕激素比例失调可能与乳腺癌的发生有关

Breast Cancer Res Treat:新的猜想:雌孕激素比例失调可能与乳腺癌的发生有关 肥胖与多种恶性肿瘤发生有关,然而多年来困扰我们的一个难题是:为什么肥胖增加绝经后女性乳腺癌的发生,却减少绝经前乳腺癌的发生?伦敦大学的Mitch Dowsett和Elizabeth Folkerd将给大家揭开这个谜底。 1.      

AJOG:BMI对孕激素类药物预防早产疗效的影响

早产是导致新生儿死亡及短期或长期致残的主要原因,其中40%的早产发生在妊娠34周前,20%发生在32周前。妊娠34周前的早产占围产儿死亡及病率的50%。如何延长孕周以降低围产儿死亡率及病率是早产防治的关键。2003年《新英格兰医学杂志》刊登的一篇随机对照临床试验结果表明,每周注射17α-己酸羟孕酮可减少既往有早产史的单胎孕妇复发性早产的发生,降低婴儿严重并发症的发生风险。随后陆续有相关研究报道证实

PLoS Pathog:孕激素可帮助女性抵御流感?

黄体酮是由卵巢黄体分泌的一种天然孕激素,在体内对雌激素激发过的子宫内膜有显著形态学影响,为维持妊娠所必需。孕激素是女性口服避孕药的主要成分,全世界约有1亿名成年年轻女性口服孕激素。在美国,每年有数百万人感染流感,成千上万名患者住院,成千上万名患者死亡。育龄女性出现流感感染并发症的几率是男性的两倍。令人惊讶的是,尽管大量的女性服用孕酮受体药物,却很少知道机体激素与感染的关系,对性传播疾病也知之甚少。